Stephens resumed coverage on Establishment Labs with a new price target
$ESTA
Industrial Specialties
Health Care
Stephens resumed coverage of Establishment Labs with a rating of Overweight and set a new price target of $90.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/14/2025 | Hold | Needham | |
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
| 10/13/2022 | $70.00 | Buy | Mizuho |
| 8/24/2022 | $107.00 | Buy | B. Riley Securities |
| 11/10/2021 | $88.00 → $90.00 | Overweight | Stephens & Co. |
DEFA14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
DEF 14A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
SCHEDULE 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $44.5 million, consistent with preannouncement on January 13. Motiva Implants approved and launched in U.S.; Motiva U.S. revenue in the fourth quarter of $3.3 million. Fourth quarter net loss from operations of $18.7 million, a 15% reduction compared to a net loss of $22.1 million in the year-ago period. F
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13750828. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.e
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13749629. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.est
Needham initiated coverage of Establishment Labs with a rating of Hold
Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00
JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, provided preliminary first quarter 2025 sales results and announced that it will host an analyst and investor event in New York City on June 12, 2025. Establishment Labs' preliminary unaudited revenue for the first quarter of 2025 is expected to be approximately $41.4 million, including approximately $6.2 million from Motiva sales in the United States. On June 12, Establishment Labs' leadership team and invited plastic surgeons will present an update on the recent launch of Motiva in the United States,
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include five-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic MEET 2025, the annual meeting of The Aesthetic Society, in Austin, Texas. Dr. Glicksman will present data for the 451 primary augmentation patients enrolled in the study through the five-year follow-up vi
The campaign is the first-of-its-kind partnership and follows the US FDA approval of Motiva Implants® NEW YORK, March 6, 2025 /PRNewswire/ -- Establishment Labs® Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a partnership with GRAMMY Award-winning hitmaker Meghan Trainor. Meghan recently received Motiva Implants® after careful consideration and research. "Self-confidence and body positivity are so important to me. After losing a bunch of weight and having two kids, I have always struggled loving my breasts because they were
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Raj Denhoy as Chief Financial Officer effective immediately. Mr. Denhoy has been with the company since February 2021, including as Interim Chief Financial Officer since August. "Raj has quickly become a trusted and vital colleague to me and many others at Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "His depth of knowledge about our business and industry are matched by a clear vision of what we must do to achieve success as
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)